{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:04:23Z","timestamp":1785517463886,"version":"3.56.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06090-6","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:24:45Z","timestamp":1785515085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review"],"prefix":"10.1007","volume":"63","author":[{"given":"Shuhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1635-9902","authenticated-orcid":false,"given":"Guangzhi","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"6090_CR1","doi-asserted-by":"publisher","first-page":"102598","DOI":"10.1016\/j.arr.2024.102598","volume":"103","author":"Y Lu","year":"2025","unstructured":"Lu Y, Shang Z, Zhang W et al (2025) Global, regional, and national burden of spinal cord injury from 1990 to 2021 and projections for 2050: a systematic analysis for the Global Burden of Disease 2021 study. Ageing Res Rev 103:102598. https:\/\/doi.org\/10.1016\/j.arr.2024.102598","journal-title":"Ageing Res Rev"},{"issue":"2","key":"6090_CR2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ncl.2021.02.004","volume":"39","author":"I Eli","year":"2021","unstructured":"Eli I, Lerner DP, Ghogawala Z (2021) Acute traumatic spinal cord injury. Neurol Clin 39(2):471\u2013488. https:\/\/doi.org\/10.1016\/j.ncl.2021.02.004","journal-title":"Neurol Clin"},{"issue":"9304","key":"6090_CR3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(02)07603-1","volume":"359","author":"JW McDonald","year":"2002","unstructured":"McDonald JW, Sadowsky C (2002) Spinal-cord injury. Lancet 359(9304):417\u2013425. https:\/\/doi.org\/10.1016\/S0140-6736(02)07603-1","journal-title":"Lancet"},{"issue":"1","key":"6090_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-023-01477-6","volume":"8","author":"X Hu","year":"2023","unstructured":"Hu X, Xu W, Ren Y et al (2023) Spinal cord injury: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 8(1):245. https:\/\/doi.org\/10.1038\/s41392-023-01477-6","journal-title":"Signal Transduct Target Ther"},{"key":"6090_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jot.2019.10.006","volume":"20","author":"H Huang","year":"2020","unstructured":"Huang H, Young W, Skaper S et al (2020) Clinical neurorestorative therapeutic guidelines for spinal cord injury (IANR\/CANR version 2019). J Orthop Translat 20:14\u201324. https:\/\/doi.org\/10.1016\/j.jot.2019.10.006","journal-title":"J Orthop Translat"},{"issue":"3","key":"6090_CR6","doi-asserted-by":"publisher","first-page":"100205","DOI":"10.1016\/j.jnrt.2025.100205","volume":"13","author":"Z Liu","year":"2025","unstructured":"Liu Z, Lin Z, Liu X, Xie X, Tan C (2025) Application and progress of magnetic field therapy for spinal cord injury. Journal of Neurorestoratology 13(3):100205. https:\/\/doi.org\/10.1016\/j.jnrt.2025.100205","journal-title":"Journal of Neurorestoratology"},{"issue":"6","key":"6090_CR7","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1007\/s00586-023-07716-2","volume":"32","author":"M Zhou","year":"2023","unstructured":"Zhou M, Zhong H, Xing C et al (2023) Comparison of clinical outcomes associated with spinal cord stimulation (SCS) or conventional medical management (CMM) for chronic pain: a systematic review and meta-analysis. Eur Spine J 32(6):2029\u20132041. https:\/\/doi.org\/10.1007\/s00586-023-07716-2","journal-title":"Eur Spine J"},{"issue":"1","key":"6090_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00701-025-06443-5","volume":"167","author":"M Zhou","year":"2025","unstructured":"Zhou M, Xu Z, Feng L et al (2025) 50 years of methylprednisolone application in spinal cord injury: a bibliometric analysis. Acta Neurochir 167(1):38. https:\/\/doi.org\/10.1007\/s00701-025-06443-5","journal-title":"Acta Neurochir"},{"issue":"4","key":"6090_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/ATN.ATN-D-25-00014","volume":"2","author":"H Zhong","year":"2025","unstructured":"Zhong H, Wang H, Huang B et al (2025) Current frontier technologies in spinal cord injury research: a narrative review. Adv Technol Neurosci 2(4):173. https:\/\/doi.org\/10.4103\/ATN.ATN-D-25-00014","journal-title":"Adv Technol Neurosci"},{"issue":"9","key":"6090_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11910-019-0984-1","volume":"19","author":"M Karsy","year":"2019","unstructured":"Karsy M, Hawryluk G (2019) Modern medical management of spinal cord injury. Curr Neurol Neurosci Rep 19(9):65. https:\/\/doi.org\/10.1007\/s11910-019-0984-1","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"6090_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043824","volume":"24","author":"ZZ Khaing","year":"2023","unstructured":"Khaing ZZ, Chen JY, Safarians G et al (2023) Clinical trials targeting secondary damage after traumatic spinal cord injury. Int J Mol Sci 24(4):3824. https:\/\/doi.org\/10.3390\/ijms24043824","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6090_CR12","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911505","volume":"12","author":"JM Griffin","year":"2020","unstructured":"Griffin JM, Bradke F (2020) Therapeutic repair for spinal cord injury: combinatory approaches to address a multifaceted problem. EMBO Mol Med 12(3):e11505. https:\/\/doi.org\/10.15252\/emmm.201911505","journal-title":"EMBO Mol Med"},{"issue":"1","key":"6090_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"6090_CR14","doi-asserted-by":"publisher","first-page":"102118","DOI":"10.1016\/j.molmet.2025.102118","volume":"95","author":"TD M\u00fcller","year":"2025","unstructured":"M\u00fcller TD, Adriaenssens A, Ahr\u00e9n B et al (2025) Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab 95:102118. https:\/\/doi.org\/10.1016\/j.molmet.2025.102118","journal-title":"Mol Metab"},{"issue":"13","key":"6090_CR15","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMe2401743","volume":"390","author":"DG Standaert","year":"2024","unstructured":"Standaert DG (2024) GLP-1, Parkinson\u2019s disease, and neuroprotection. N Engl J Med 390(13):1233\u20131234. https:\/\/doi.org\/10.1056\/NEJMe2401743","journal-title":"N Engl J Med"},{"issue":"10","key":"6090_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3390\/ph17101313","volume":"17","author":"A Harej Hrka\u0107","year":"2024","unstructured":"Harej Hrka\u0107 A, Pilipovi\u0107 K, Belan\u010di\u0107 A, Jureti\u0107 L, Vitezi\u0107 D, Mr\u0161i\u0107-Pel\u010di\u0107 J (2024) The therapeutic potential of glucagon-like peptide 1 receptor agonists in traumatic brain injury. Pharmaceuticals (Basel) 17(10):1313. https:\/\/doi.org\/10.3390\/ph17101313","journal-title":"Pharmaceuticals (Basel)"},{"issue":"13","key":"6090_CR17","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C et al (2024) Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"key":"6090_CR18","doi-asserted-by":"publisher","first-page":"102343","DOI":"10.1016\/j.arr.2024.102343","volume":"98","author":"KO Kopp","year":"2024","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Lahiri DK, Greig NH (2024) Type 2 diabetes mellitus\/obesity drugs: a neurodegenerative disorders savior or a bridge too far? Ageing Res Rev 98:102343. https:\/\/doi.org\/10.1016\/j.arr.2024.102343","journal-title":"Ageing Res Rev"},{"issue":"1","key":"6090_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1210\/endrev\/bnac018","volume":"44","author":"JM Yabut","year":"2023","unstructured":"Yabut JM, Drucker DJ (2023) Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev 44(1):14\u201332. https:\/\/doi.org\/10.1210\/endrev\/bnac018","journal-title":"Endocr Rev"},{"issue":"6742","key":"6090_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0548","volume":"388","author":"Y Yang","year":"2025","unstructured":"Yang Y, Hao C, Jiao T et al (2025) Osteoarthritis treatment via the GLP-1-mediated gut-joint axis targets intestinal FXR signaling. Science 388(6742):eadt0548. https:\/\/doi.org\/10.1126\/science.adt0548","journal-title":"Science"},{"issue":"1","key":"6090_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s10194-024-01821-3","volume":"25","author":"W Halloum","year":"2024","unstructured":"Halloum W, Dughem YA, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain 25(1):112. https:\/\/doi.org\/10.1186\/s10194-024-01821-3","journal-title":"J Headache Pain"},{"key":"6090_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ibneur.2023.09.003","volume":"15","author":"S Nomura","year":"2023","unstructured":"Nomura S, Katoh H, Yanagisawa S, Noguchi T, Okada K, Watanabe M (2023) Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress. IBRO Neurosci Rep 15:225\u2013234. https:\/\/doi.org\/10.1016\/j.ibneur.2023.09.003","journal-title":"IBRO Neurosci Rep"},{"issue":"6","key":"6090_CR23","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1007\/s12035-015-9327-7","volume":"53","author":"HT Li","year":"2016","unstructured":"Li HT, Zhao XZ, Zhang XR et al (2016) Exendin-4 enhances motor function recovery via promotion of autophagy and inhibition of neuronal apoptosis after spinal cord injury in rats. Mol Neurobiol 53(6):4073\u20134082. https:\/\/doi.org\/10.1007\/s12035-015-9327-7","journal-title":"Mol Neurobiol"},{"issue":"15","key":"6090_CR24","doi-asserted-by":"publisher","first-page":"8687","DOI":"10.1111\/jcmm.15501","volume":"24","author":"W Han","year":"2020","unstructured":"Han W, Li Y, Cheng J et al (2020) Sitagliptin improves functional recovery via GLP-1R-induced anti-apoptosis and facilitation of axonal regeneration after spinal cord injury. J Cell Mol Med 24(15):8687\u20138702. https:\/\/doi.org\/10.1111\/jcmm.15501","journal-title":"J Cell Mol Med"},{"key":"6090_CR25","doi-asserted-by":"publisher","first-page":"1342944","DOI":"10.3389\/fnins.2024.1342944","volume":"18","author":"T Noguchi","year":"2024","unstructured":"Noguchi T, Katoh H, Nomura S, Okada K, Watanabe M (2024) The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype. Front Neurosci 18:1342944. https:\/\/doi.org\/10.3389\/fnins.2024.1342944","journal-title":"Front Neurosci"},{"issue":"6","key":"6090_CR26","doi-asserted-by":"publisher","first-page":"e14806","DOI":"10.1111\/cns.14806","volume":"30","author":"B Guo","year":"2024","unstructured":"Guo B, Qi M, Luo X et al (2024) GIP attenuates neuronal oxidative stress by regulating glucose uptake in spinal cord injury of rat. CNS Neurosci Ther 30(6):e14806. https:\/\/doi.org\/10.1111\/cns.14806","journal-title":"CNS Neurosci Ther"},{"key":"6090_CR27","unstructured":"Global burden of spinal cord injury: future directions - PubMed. Accessed May 9, 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/37863598\/"},{"issue":"4","key":"6090_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1310\/sci2304-353","volume":"23","author":"JM Clark","year":"2017","unstructured":"Clark JM, Marshall R (2017) Nature of the non-traumatic spinal cord injury literature: a systematic review. Top Spinal Cord Inj Rehabil 23(4):353\u2013367. https:\/\/doi.org\/10.1310\/sci2304-353","journal-title":"Top Spinal Cord Inj Rehabil"},{"issue":"1","key":"6090_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12916-024-03514-9","volume":"22","author":"Y Lu","year":"2024","unstructured":"Lu Y, Shang Z, Zhang W et al (2024) Global incidence and characteristics of spinal cord injury since 2000\u20132021: a systematic review and meta-analysis. BMC Med 22(1):285. https:\/\/doi.org\/10.1186\/s12916-024-03514-9","journal-title":"BMC Med"},{"issue":"20","key":"6090_CR30","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.3390\/ijms21207533","volume":"21","author":"A Anjum","year":"2020","unstructured":"Anjum A, Yazid MD, Fauzi Daud M et al (2020) Spinal cord injury: pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci 21(20):7533. https:\/\/doi.org\/10.3390\/ijms21207533","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6090_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12974-021-02337-2","volume":"18","author":"DJ Hellenbrand","year":"2021","unstructured":"Hellenbrand DJ, Quinn CM, Piper ZJ, Morehouse CN, Fixel JA, Hanna AS (2021) Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration. J Neuroinflammation 18(1):284. https:\/\/doi.org\/10.1186\/s12974-021-02337-2","journal-title":"J Neuroinflammation"},{"key":"6090_CR32","doi-asserted-by":"publisher","first-page":"1084101","DOI":"10.3389\/fimmu.2022.1084101","volume":"13","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Sterner RM (2022) Immune response following traumatic spinal cord injury: pathophysiology and therapies. Front Immunol 13:1084101. https:\/\/doi.org\/10.3389\/fimmu.2022.1084101","journal-title":"Front Immunol"},{"key":"6090_CR33","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fneur.2019.00282","volume":"10","author":"A Alizadeh","year":"2019","unstructured":"Alizadeh A, Dyck SM, Karimi-Abdolrezaee S (2019) Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms. Front Neurol 10:282. https:\/\/doi.org\/10.3389\/fneur.2019.00282","journal-title":"Front Neurol"},{"issue":"3","key":"6090_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.nec.2021.03.002","volume":"32","author":"LD Hachem","year":"2021","unstructured":"Hachem LD, Fehlings MG (2021) Pathophysiology of spinal cord injury. Neurosurg Clin N Am 32(3):305\u2013313. https:\/\/doi.org\/10.1016\/j.nec.2021.03.002","journal-title":"Neurosurg Clin N Am"},{"issue":"6","key":"6090_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cells12060853","volume":"12","author":"T Clifford","year":"2023","unstructured":"Clifford T, Finkel Z, Rodriguez B, Joseph A, Cai L (2023) Current advancements in spinal cord injury research-glial scar formation and neural regeneration. Cells 12(6):853. https:\/\/doi.org\/10.3390\/cells12060853","journal-title":"Cells"},{"key":"6090_CR36","doi-asserted-by":"publisher","first-page":"711564","DOI":"10.3389\/fncir.2021.711564","volume":"15","author":"C Guo","year":"2021","unstructured":"Guo C, Ma YY (2021) Calcium permeable-AMPA receptors and excitotoxicity in neurological disorders. Front Neural Circuits 15:711564. https:\/\/doi.org\/10.3389\/fncir.2021.711564","journal-title":"Front Neural Circuits"},{"key":"6090_CR37","doi-asserted-by":"publisher","first-page":"121814","DOI":"10.1016\/j.lfs.2023.121814","volume":"328","author":"D Neves","year":"2023","unstructured":"Neves D, Salazar IL, Almeida RD, Silva RM (2023) Molecular mechanisms of ischemia and glutamate excitotoxicity. Life Sci 328:121814. https:\/\/doi.org\/10.1016\/j.lfs.2023.121814","journal-title":"Life Sci"},{"key":"6090_CR38","doi-asserted-by":"publisher","first-page":"tkab035","DOI":"10.1093\/burnst\/tkab035","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yang S, Liu C, Han X, Gu X, Zhou S (2021) Deciphering glial scar after spinal cord injury. Burns Trauma 9:tkab035. https:\/\/doi.org\/10.1093\/burnst\/tkab035","journal-title":"Burns Trauma"},{"issue":"18","key":"6090_CR39","doi-asserted-by":"publisher","first-page":"6316","DOI":"10.1523\/JNEUROSCI.4912-13.2014","volume":"34","author":"AD Greenhalgh","year":"2014","unstructured":"Greenhalgh AD, David S (2014) Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J Neurosci 34(18):6316\u20136322. https:\/\/doi.org\/10.1523\/JNEUROSCI.4912-13.2014","journal-title":"J Neurosci"},{"issue":"1","key":"6090_CR40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41467-019-08446-0","volume":"10","author":"V Bellver-Landete","year":"2019","unstructured":"Bellver-Landete V, Bretheau F, Mailhot B et al (2019) Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury. Nat Commun 10(1):518. https:\/\/doi.org\/10.1038\/s41467-019-08446-0","journal-title":"Nat Commun"},{"issue":"7835","key":"6090_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41586-020-2795-6","volume":"587","author":"Y Li","year":"2020","unstructured":"Li Y, He X, Kawaguchi R et al (2020) Microglia-organized scar-free spinal cord repair in neonatal mice. Nature 587(7835):613\u2013618. https:\/\/doi.org\/10.1038\/s41586-020-2795-6","journal-title":"Nature"},{"issue":"2","key":"6090_CR42","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12264-022-00897-8","volume":"39","author":"L Gong","year":"2023","unstructured":"Gong L, Gu Y, Han X et al (2023) Spatiotemporal dynamics of the molecular expression pattern and intercellular interactions in the glial scar response to spinal cord injury. Neurosci Bull 39(2):213\u2013244. https:\/\/doi.org\/10.1007\/s12264-022-00897-8","journal-title":"Neurosci Bull"},{"issue":"1","key":"6090_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12565-024-00778-2","volume":"100","author":"M Boulton","year":"2025","unstructured":"Boulton M, Al-Rubaie A (2025) Neuroinflammation and neurodegeneration following traumatic brain injuries. Anat Sci Int 100(1):3\u201314. https:\/\/doi.org\/10.1007\/s12565-024-00778-2","journal-title":"Anat Sci Int"},{"issue":"10","key":"6090_CR44","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1242\/dmm.025833","volume":"9","author":"J Kjell","year":"2016","unstructured":"Kjell J, Olson L (2016) Rat models of spinal cord injury: from pathology to potential therapies. Dis Model Mech 9(10):1125\u20131137. https:\/\/doi.org\/10.1242\/dmm.025833","journal-title":"Dis Model Mech"},{"issue":"21","key":"6090_CR45","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1089\/neu.2020.7587","volume":"38","author":"PD Cerro","year":"2021","unstructured":"Cerro PD, Barriga-Mart\u00edn A, Vara H, Romero-Mu\u00f1oz LM, Rodr\u00edguez-De-Lope \u00c1, Collazos-Castro JE (2021) Neuropathological and motor impairments after incomplete cervical spinal cord injury in pigs. J Neurotrauma 38(21):2956\u20132977. https:\/\/doi.org\/10.1089\/neu.2020.7587","journal-title":"J Neurotrauma"},{"issue":"7","key":"6090_CR46","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nm.4354","volume":"23","author":"M Hara","year":"2017","unstructured":"Hara M, Kobayakawa K, Ohkawa Y et al (2017) Interaction of reactive astrocytes with type I collagen induces astrocytic scar formation through the integrin-N-cadherin pathway after spinal cord injury. Nat Med 23(7):818\u2013828. https:\/\/doi.org\/10.1038\/nm.4354","journal-title":"Nat Med"},{"issue":"12","key":"6090_CR47","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1007\/s12035-021-02533-4","volume":"58","author":"J Alizadeh","year":"2021","unstructured":"Alizadeh J, Kochan MM, Stewart VD, Drewnik DA, Hannila SS, Ghavami S (2021) Inhibition of autophagy flux promotes secretion of chondroitin sulfate proteoglycans in primary rat astrocytes. Mol Neurobiol 58(12):6077\u20136091. https:\/\/doi.org\/10.1007\/s12035-021-02533-4","journal-title":"Mol Neurobiol"},{"key":"6090_CR48","doi-asserted-by":"publisher","first-page":"114264","DOI":"10.1016\/j.expneurol.2022.114264","volume":"359","author":"T Tamaru","year":"2023","unstructured":"Tamaru T, Kobayakawa K, Saiwai H et al (2023) Glial scar survives until the chronic phase by recruiting scar-forming astrocytes after spinal cord injury. Exp Neurol 359:114264. https:\/\/doi.org\/10.1016\/j.expneurol.2022.114264","journal-title":"Exp Neurol"},{"key":"6090_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.expneurol.2014.01.013","volume":"254","author":"TA Evans","year":"2014","unstructured":"Evans TA, Barkauskas DS, Myers JT et al (2014) High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury. Exp Neurol 254:109\u2013120. https:\/\/doi.org\/10.1016\/j.expneurol.2014.01.013","journal-title":"Exp Neurol"},{"issue":"1","key":"6090_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12974-022-02408-y","volume":"19","author":"E Kamma","year":"2022","unstructured":"Kamma E, Lasisi W, Libner C, Ng HS, Plemel JR (2022) Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. J Neuroinflammation 19(1):45. https:\/\/doi.org\/10.1186\/s12974-022-02408-y","journal-title":"J Neuroinflammation"},{"key":"6090_CR51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.expneurol.2013.04.003","volume":"247","author":"JC Pendleton","year":"2013","unstructured":"Pendleton JC, Shamblott MJ, Gary DS et al (2013) Chondroitin sulfate proteoglycans inhibit oligodendrocyte myelination through PTP\u03c3. Exp Neurol 247:113\u2013121. https:\/\/doi.org\/10.1016\/j.expneurol.2013.04.003","journal-title":"Exp Neurol"},{"issue":"1","key":"6090_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/glia.23533","volume":"67","author":"S Dyck","year":"2019","unstructured":"Dyck S, Kataria H, Akbari-Kelachayeh K, Silver J, Karimi-Abdolrezaee S (2019) LAR and PTP\u03c3 receptors are negative regulators of oligodendrogenesis and oligodendrocyte integrity in spinal cord injury. Glia 67(1):125\u2013145. https:\/\/doi.org\/10.1002\/glia.23533","journal-title":"Glia"},{"issue":"6039","key":"6090_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1126\/science.1203165","volume":"333","author":"C G\u00f6ritz","year":"2011","unstructured":"G\u00f6ritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Fris\u00e9n J (2011) A pericyte origin of spinal cord scar tissue. Science 333(6039):238\u2013242. https:\/\/doi.org\/10.1126\/science.1203165","journal-title":"Science"},{"issue":"4","key":"6090_CR54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.devcel.2020.12.009","volume":"56","author":"V Tsata","year":"2021","unstructured":"Tsata V, M\u00f6llmert S, Schweitzer C et al (2021) A switch in pdgfrb+ cell-derived ECM composition prevents inhibitory scarring and promotes axon regeneration in the zebrafish spinal cord. Dev Cell 56(4):509-524.e9. https:\/\/doi.org\/10.1016\/j.devcel.2020.12.009","journal-title":"Dev Cell"},{"issue":"1","key":"6090_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46292\/sci20-00067","volume":"27","author":"DR Gater","year":"2021","unstructured":"Gater DR, Farkas GJ, Tiozzo E (2021) Pathophysiology of neurogenic obesity after spinal cord injury. Top Spinal Cord Inj Rehabil 27(1):1\u201310. https:\/\/doi.org\/10.46292\/sci20-00067","journal-title":"Top Spinal Cord Inj Rehabil"},{"issue":"1","key":"6090_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.46292\/sci20-00079","volume":"27","author":"DR Gater","year":"2021","unstructured":"Gater DR, Farkas GJ, Dolbow DR, Berg A, Gorgey AS (2021) Body composition and metabolic assessment after motor complete spinal cord injury: development of a clinically relevant equation to estimate body fat. Top Spinal Cord Inj Rehabil 27(1):11\u201322. https:\/\/doi.org\/10.46292\/sci20-00079","journal-title":"Top Spinal Cord Inj Rehabil"},{"issue":"3","key":"6090_CR57","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2340\/16501977-0510","volume":"42","author":"K Wahman","year":"2010","unstructured":"Wahman K, Nash MS, Westgren N, Lewis JE, Seiger A, Levi R (2010) Cardiovascular disease risk factors in persons with paraplegia: the Stockholm spinal cord injury study. J Rehabil Med 42(3):272\u2013278. https:\/\/doi.org\/10.2340\/16501977-0510","journal-title":"J Rehabil Med"},{"issue":"1","key":"6090_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/10790268.2017.1423266","volume":"42","author":"DR Gater","year":"2019","unstructured":"Gater DR, Farkas GJ, Berg AS, Castillo C (2019) Prevalence of metabolic syndrome in veterans with spinal cord injury. J Spinal Cord Med 42(1):86\u201393. https:\/\/doi.org\/10.1080\/10790268.2017.1423266","journal-title":"J Spinal Cord Med"},{"issue":"7","key":"6090_CR59","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.sc.3102171","volume":"46","author":"Y Maruyama","year":"2008","unstructured":"Maruyama Y, Mizuguchi M, Yaginuma T et al (2008) Serum leptin, abdominal obesity and the metabolic syndrome in individuals with chronic spinal cord injury. Spinal Cord 46(7):494\u2013499. https:\/\/doi.org\/10.1038\/sj.sc.3102171","journal-title":"Spinal Cord"},{"key":"6090_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2024.114847","volume":"379","author":"MT Goodus","year":"2024","unstructured":"Goodus MT, Alfredo AN, Carson KE et al (2024) Spinal cord injury-induced metabolic impairment and steatohepatitis develops in non-obese rats and is exacerbated by premorbid obesity. Exp Neurol 379:114847. https:\/\/doi.org\/10.1016\/j.expneurol.2024.114847","journal-title":"Exp Neurol"},{"key":"6090_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108672","volume":"112","author":"Z Chen","year":"2019","unstructured":"Chen Z, Guo H, Lu Z, Sun K, Jin Q (2019) Hyperglycemia aggravates spinal cord injury through endoplasmic reticulum stress mediated neuronal apoptosis, gliosis and activation. Biomed Pharmacother 112:108672. https:\/\/doi.org\/10.1016\/j.biopha.2019.108672","journal-title":"Biomed Pharmacother"},{"key":"6090_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.140453","volume":"301","author":"M Wu","year":"2025","unstructured":"Wu M, Zhang S, Wu X et al (2025) Acute hyperglycemia impedes spinal cord injury recovery via triggering excessive ferroptosis of endothelial cells. Int J Biol Macromol 301:140453. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140453","journal-title":"Int J Biol Macromol"},{"issue":"10","key":"6090_CR63","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"Drucker DJ, Holst JJ (2023) The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66(10):1765\u20131779. https:\/\/doi.org\/10.1007\/s00125-023-05906-7","journal-title":"Diabetologia"},{"issue":"9","key":"6090_CR64","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","volume":"35","author":"JE Campbell","year":"2023","unstructured":"Campbell JE, M\u00fcller TD, Finan B, DiMarchi RD, Tsch\u00f6p MH, D\u2019Alessio DA (2023) GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applications. Cell Metab 35(9):1519\u20131529. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.010","journal-title":"Cell Metab"},{"issue":"4","key":"6090_CR65","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, Heller RS, Kirk RK et al (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155(4):1280\u20131290. https:\/\/doi.org\/10.1210\/en.2013-1934","journal-title":"Endocrinology"},{"issue":"Suppl 1","key":"6090_CR66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ (2018) Incretin hormones: their role in health and disease. Diabetes Obes Metab 20(Suppl 1):5\u201321. https:\/\/doi.org\/10.1111\/dom.13129","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6090_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/00207454.2021.1924707","volume":"133","author":"L Zhang","year":"2023","unstructured":"Zhang L, Zhang W, Tian X (2023) The pleiotropic of GLP-1\/GLP-1R axis in central nervous system diseases. Int J Neurosci 133(5):473\u2013491. https:\/\/doi.org\/10.1080\/00207454.2021.1924707","journal-title":"Int J Neurosci"},{"issue":"3","key":"6090_CR68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/neu.2015.3877","volume":"33","author":"ABW Marcos","year":"2016","unstructured":"Marcos ABW, Forner S, Martini AC et al (2016) Temporal and regional expression of glucose-dependent insulinotropic peptide and its receptor in spinal cord injured rats. J Neurotrauma 33(3):261\u2013268. https:\/\/doi.org\/10.1089\/neu.2015.3877","journal-title":"J Neurotrauma"},{"key":"6090_CR69","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fendo.2020.00178","volume":"11","author":"MP Gilbert","year":"2020","unstructured":"Gilbert MP, Pratley RE (2020) GLP-1 Analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne) 11:178. https:\/\/doi.org\/10.3389\/fendo.2020.00178","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"6090_CR70","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/ph15060740","volume":"15","author":"L Sun","year":"2022","unstructured":"Sun L, Zheng ZM, Shao CS et al (2022) Rational design by structural biology of industrializable, long-acting antihyperglycemic GLP-1 receptor agonists. Pharmaceuticals (Basel) 15(6):740. https:\/\/doi.org\/10.3390\/ph15060740","journal-title":"Pharmaceuticals (Basel)"},{"key":"6090_CR71","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D et al (2024) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410","journal-title":"BMJ"},{"issue":"10295","key":"6090_CR72","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143\u2013155. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"issue":"6","key":"6090_CR73","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"issue":"3","key":"6090_CR74","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","volume":"21","author":"CH Lin","year":"2020","unstructured":"Lin CH, Shao L, Zhang YM et al (2020) An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother 21(3):275\u2013285. https:\/\/doi.org\/10.1080\/14656566.2019.1695779","journal-title":"Expert Opin Pharmacother"},{"issue":"17","key":"6090_CR75","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s40265-014-0320-7","volume":"74","author":"M Sanford","year":"2014","unstructured":"Sanford M (2014) Dulaglutide: first global approval. Drugs 74(17):2097\u20132103. https:\/\/doi.org\/10.1007\/s40265-014-0320-7","journal-title":"Drugs"},{"issue":"10278","key":"6090_CR76","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"issue":"2","key":"6090_CR77","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/dom.15360","volume":"26","author":"K Chen","year":"2024","unstructured":"Chen K, Chen L, Shan Z et al (2024) Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study. Diabetes Obes Metab 26(2):690\u2013698. https:\/\/doi.org\/10.1111\/dom.15360","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6090_CR78","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","volume":"18","author":"FK Knop","year":"2017","unstructured":"Knop FK, Br\u00f8nden A, Vilsb\u00f8ll T (2017) Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 18(6):555\u2013571. https:\/\/doi.org\/10.1080\/14656566.2017.1282463","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"6090_CR79","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/phar.1962","volume":"37","author":"JM Trujillo","year":"2017","unstructured":"Trujillo JM, Goldman J (2017) Lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes. Pharmacotherapy 37(8):927\u2013943. https:\/\/doi.org\/10.1002\/phar.1962","journal-title":"Pharmacotherapy"},{"issue":"1","key":"6090_CR80","doi-asserted-by":"publisher","first-page":"19041","DOI":"10.1038\/s41598-023-46274-x","volume":"13","author":"HM Salamah","year":"2023","unstructured":"Salamah HM, Marey A, Elsayed E et al (2023) Efficacy and safety of polyethylene glycol loxenatide in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 13(1):19041. https:\/\/doi.org\/10.1038\/s41598-023-46274-x","journal-title":"Sci Rep"},{"issue":"8","key":"6090_CR81","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s40265-014-0228-2","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM, Nowlan ML (2014) Albiglutide: first global approval. Drugs 74(8):929\u2013938. https:\/\/doi.org\/10.1007\/s40265-014-0228-2","journal-title":"Drugs"},{"key":"6090_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112722","volume":"148","author":"X Sun","year":"2022","unstructured":"Sun X, Zhang Z, Liu M et al (2022) Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives. Biomed Pharmacother 148:112722. https:\/\/doi.org\/10.1016\/j.biopha.2022.112722","journal-title":"Biomed Pharmacother"},{"issue":"10400","key":"6090_CR83","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0140-6736(23)01201-1","volume":"402","author":"MA Nauck","year":"2023","unstructured":"Nauck MA, Horowitz M (2023) Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. Lancet 402(10400):429\u2013431. https:\/\/doi.org\/10.1016\/S0140-6736(23)01201-1","journal-title":"Lancet"},{"issue":"Supplement_1","key":"6090_CR84","doi-asserted-by":"publisher","DOI":"10.2337\/db23-56-OR","volume":"72","author":"FK Knop","year":"2023","unstructured":"Knop FK, Urva S, Rettiganti M et al (2023) 56-OR: a long-acting glucose-dependent insulinotropic polypeptide receptor agonist shows weight loss without nausea or vomiting. Diabetes 72(Supplement_1):56-OR. https:\/\/doi.org\/10.2337\/db23-56-OR","journal-title":"Diabetes"},{"key":"6090_CR85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 18:3\u201314. https:\/\/doi.org\/10.1016\/j.molmet.2018.09.009","journal-title":"Mol Metab"},{"key":"6090_CR86","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","volume":"63","author":"PJ Knerr","year":"2022","unstructured":"Knerr PJ, Mowery SA, Douros JD et al (2022) Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice. Mol Metab 63:101533. https:\/\/doi.org\/10.1016\/j.molmet.2022.101533","journal-title":"Mol Metab"},{"issue":"6","key":"6090_CR87","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP et al (2023) Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 389(6):514\u2013526. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"6090_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1438318","volume":"16","author":"MA Karimi","year":"2025","unstructured":"Karimi MA, Gholami Chahkand MS, Dadkhah PA et al (2025) Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis. Front Pharmacol 16:1438318. https:\/\/doi.org\/10.3389\/fphar.2025.1438318","journal-title":"Front Pharmacol"},{"key":"6090_CR89","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-00775","author":"A Saeed","year":"2025","unstructured":"Saeed A, Mulukutla SR, Thoma F et al (2025) Comparison of semaglutide or dulaglutide versus empagliflozin for risk for death and cardiovascular outcomes among patients with type 2 diabetes\u202f: two target trial emulation studies. Ann Intern Med. https:\/\/doi.org\/10.7326\/ANNALS-24-00775","journal-title":"Ann Intern Med"},{"issue":"1","key":"6090_CR90","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao F, Zhou Q, Cong Z et al (2022) Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun 13(1):1057. https:\/\/doi.org\/10.1038\/s41467-022-28683-0","journal-title":"Nat Commun"},{"issue":"1","key":"6090_CR91","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 21(1):169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"6090_CR92","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","volume":"30","author":"PP Gleason","year":"2024","unstructured":"Gleason PP, Urick BY, Marshall LZ, Friedlander N, Qiu Y, Leslie RS (2024) Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. J Manag Care Spec Pharm 30(8):860\u2013867. https:\/\/doi.org\/10.18553\/jmcp.2024.23332","journal-title":"J Manag Care Spec Pharm"},{"issue":"14","key":"6090_CR93","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1016\/j.cell.2022.05.007","volume":"185","author":"T Zhang","year":"2022","unstructured":"Zhang T, Perkins MH, Chang H, Han W, de Araujo IE (2022) An inter-organ neural circuit for appetite suppression. Cell 185(14):2478-2494.e28. https:\/\/doi.org\/10.1016\/j.cell.2022.05.007","journal-title":"Cell"},{"key":"6090_CR94","doi-asserted-by":"publisher","first-page":"101181","DOI":"10.1016\/j.molmet.2021.101181","volume":"49","author":"A Novikoff","year":"2021","unstructured":"Novikoff A, O\u2019Brien SL, Bernecker M et al (2021) Spatiotemporal GLP-1 and GIP receptor signaling and trafficking\/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab 49:101181. https:\/\/doi.org\/10.1016\/j.molmet.2021.101181","journal-title":"Mol Metab"},{"issue":"6","key":"6090_CR95","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2337\/db20-0998","volume":"70","author":"JI Bagger","year":"2021","unstructured":"Bagger JI, Gr\u00f8ndahl MFG, Lund A, Holst JJ, Vilsb\u00f8ll T, Knop FK (2021) Glucagonostatic potency of GLP-1 in patients with type 2 diabetes, patients with type 1 diabetes, and healthy control subjects. Diabetes 70(6):1347\u20131356. https:\/\/doi.org\/10.2337\/db20-0998","journal-title":"Diabetes"},{"issue":"17","key":"6090_CR96","doi-asserted-by":"publisher","first-page":"e13852","DOI":"10.14814\/phy2.13852","volume":"6","author":"R Ramracheya","year":"2018","unstructured":"Ramracheya R, Chapman C, Chibalina M et al (2018) GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca2+ channels. Physiol Rep 6(17):e13852. https:\/\/doi.org\/10.14814\/phy2.13852","journal-title":"Physiol Rep"},{"key":"6090_CR97","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"issue":"2","key":"6090_CR98","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jdi.13115","volume":"11","author":"Y Suganuma","year":"2020","unstructured":"Suganuma Y, Shimizu T, Sato T et al (2020) Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes. J Diabetes Investig 11(2):389\u2013399. https:\/\/doi.org\/10.1111\/jdi.13115","journal-title":"J Diabetes Investig"},{"issue":"5","key":"6090_CR99","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40265-017-0706-4","volume":"77","author":"B Geloneze","year":"2017","unstructured":"Geloneze B, de Lima-J\u00fanior JC, Velloso LA (2017) Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the brain-adipocyte axis. Drugs 77(5):493\u2013503. https:\/\/doi.org\/10.1007\/s40265-017-0706-4","journal-title":"Drugs"},{"issue":"10","key":"6090_CR100","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF et al (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124(10):4473\u20134488. https:\/\/doi.org\/10.1172\/JCI75276","journal-title":"J Clin Invest"},{"issue":"7","key":"6090_CR101","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","volume":"36","author":"A Regmi","year":"2024","unstructured":"Regmi A, Aihara E, Christe ME et al (2024) Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab 36(7):1534-1549.e7. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.010","journal-title":"Cell Metab"},{"key":"6090_CR102","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan Q, Lin S, Li Y et al (2021) A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine 63:103202. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103202","journal-title":"EBioMedicine"},{"issue":"6","key":"6090_CR103","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/hep.32235","volume":"75","author":"ER Kim","year":"2022","unstructured":"Kim ER, Park JS, Kim JH et al (2022) A GLP-1\/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome. Hepatology 75(6):1523\u20131538. https:\/\/doi.org\/10.1002\/hep.32235","journal-title":"Hepatology"},{"issue":"9","key":"6090_CR104","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/cells11091553","volume":"11","author":"B Walkowski","year":"2022","unstructured":"Walkowski B, Kleibert M, Majka M, Wojciechowska M (2022) Insight into the role of the PI3K\/Akt pathway in ischemic injury and post-infarct left ventricular remodeling in normal and diabetic heart. Cells 11(9):1553. https:\/\/doi.org\/10.3390\/cells11091553","journal-title":"Cells"},{"key":"6090_CR105","doi-asserted-by":"publisher","first-page":"792885","DOI":"10.3389\/fcvm.2022.792885","volume":"9","author":"C Fernandez Rico","year":"2022","unstructured":"Fernandez Rico C, Konate K, Josse E, Nargeot J, Barr\u00e8re-Lemaire S, Boisgu\u00e9rin P (2022) Therapeutic peptides to treat myocardial ischemia-reperfusion injury. Front Cardiovasc Med 9:792885. https:\/\/doi.org\/10.3389\/fcvm.2022.792885","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"6090_CR106","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"J Helmst\u00e4dter","year":"2020","unstructured":"Helmst\u00e4dter J, Frenis K, Filippou K et al (2020) Endothelial GLP-1 (glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol 40(1):145\u2013158. https:\/\/doi.org\/10.1161\/atv.0000615456.97862.30","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6090_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.637051","volume":"12","author":"Z Cai","year":"2021","unstructured":"Cai Z, Yuan S, Zhong Y et al (2021) Amelioration of endothelial dysfunction in diabetes: role of Takeda G protein-coupled receptor 5. Front Pharmacol 12:637051. https:\/\/doi.org\/10.3389\/fphar.2021.637051","journal-title":"Front Pharmacol"},{"key":"6090_CR108","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5783639","volume":"2018","author":"WR Shen","year":"2018","unstructured":"Shen WR, Kimura K, Ishida M et al (2018) The glucagon-like peptide-1 receptor agonist exendin-4 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption via inhibition of TNF-\u03b1 expression in macrophages. J Immunol Res 2018:5783639. https:\/\/doi.org\/10.1155\/2018\/5783639","journal-title":"J Immunol Res"},{"key":"6090_CR109","doi-asserted-by":"publisher","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","volume":"130","author":"Z Li","year":"2020","unstructured":"Li Z, Li S, Wang N, Xue P, Li Y (2020) Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R. Biomed Pharmacother 130:110523. https:\/\/doi.org\/10.1016\/j.biopha.2020.110523","journal-title":"Biomed Pharmacother"},{"key":"6090_CR110","doi-asserted-by":"publisher","first-page":"763646","DOI":"10.3389\/fendo.2021.763646","volume":"12","author":"J Yu","year":"2021","unstructured":"Yu J, Shi YC, Ping F et al (2021) Liraglutide inhibits osteoclastogenesis and improves bone loss by downregulating Trem2 in female type 1 diabetic mice: findings from transcriptomics. Front Endocrinol (Lausanne) 12:763646. https:\/\/doi.org\/10.3389\/fendo.2021.763646","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"6090_CR111","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jbmr.1898","volume":"28","author":"X Ma","year":"2013","unstructured":"Ma X, Meng J, Jia M et al (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats. J Bone Miner Res 28(7):1641\u20131652. https:\/\/doi.org\/10.1002\/jbmr.1898","journal-title":"J Bone Miner Res"},{"issue":"2","key":"6090_CR112","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","volume":"360","author":"X Wu","year":"2017","unstructured":"Wu X, Li S, Xue P, Li Y (2017) Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT), extracellular signal-related kinase (ERK)1\/2, and cAMP\/protein kinase A (PKA) signaling pathways involving \u03b2-catenin. Exp Cell Res 360(2):281\u2013291. https:\/\/doi.org\/10.1016\/j.yexcr.2017.09.018","journal-title":"Exp Cell Res"},{"key":"6090_CR113","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bone.2016.07.014","volume":"91","author":"G Mabilleau","year":"2016","unstructured":"Mabilleau G, Perrot R, Mieczkowska A et al (2016) Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption. Bone 91:102\u2013112. https:\/\/doi.org\/10.1016\/j.bone.2016.07.014","journal-title":"Bone"},{"key":"6090_CR114","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2015.01.003","volume":"74","author":"A Mieczkowska","year":"2015","unstructured":"Mieczkowska A, Bouvard B, Chappard D, Mabilleau G (2015) Glucose-dependent insulinotropic polypeptide (GIP) directly affects collagen fibril diameter and collagen cross-linking in osteoblast cultures. Bone 74:29\u201336. https:\/\/doi.org\/10.1016\/j.bone.2015.01.003","journal-title":"Bone"},{"issue":"6","key":"6090_CR115","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s12015-015-9616-6","volume":"11","author":"JL Berlier","year":"2015","unstructured":"Berlier JL, Kharroubi I, Zhang J et al (2015) Glucose-dependent insulinotropic peptide prevents serum deprivation-induced apoptosis in human bone marrow-derived mesenchymal stem cells and osteoblastic cells. Stem Cell Rev Rep 11(6):841\u2013851. https:\/\/doi.org\/10.1007\/s12015-015-9616-6","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"6090_CR116","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51352","volume":"15","author":"S Rajagopal","year":"2023","unstructured":"Rajagopal S, Alruwaili F, Mavratsas V, Serna MK, Murthy VL, Raji M (2023) Glucagon-like peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: from mechanisms of action to clinical applications. Cureus 15(12):e51352. https:\/\/doi.org\/10.7759\/cureus.51352","journal-title":"Cureus"},{"key":"6090_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191815","volume":"14","author":"M Kamiya","year":"2023","unstructured":"Kamiya M, Kimura N, Umezawa N, Hasegawa H, Yasuda S (2023) Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy. Front Immunol 14:1191815. https:\/\/doi.org\/10.3389\/fimmu.2023.1191815","journal-title":"Front Immunol"},{"issue":"9","key":"6090_CR118","doi-asserted-by":"publisher","first-page":"119300","DOI":"10.1016\/j.bbamcr.2022.119300","volume":"1869","author":"L Wu","year":"2022","unstructured":"Wu L, Zhou M, Li T et al (2022) GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway. Biochim Biophys Acta Mol Cell Res 1869(9):119300. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119300","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"2","key":"6090_CR119","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","volume":"9","author":"J Chen","year":"2018","unstructured":"Chen J, Xie JJ, Shi KS et al (2018) Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat. Cell Death Dis 9(2):212. https:\/\/doi.org\/10.1038\/s41419-017-0217-y","journal-title":"Cell Death Dis"},{"issue":"1","key":"6090_CR120","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12891-024-07640-6","volume":"25","author":"X Zhang","year":"2024","unstructured":"Zhang X, Jiang J, Xu J, Chen J, Gu Y, Wu G (2024) Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes. BMC Musculoskelet Disord 25(1):601. https:\/\/doi.org\/10.1186\/s12891-024-07640-6","journal-title":"BMC Musculoskelet Disord"},{"key":"6090_CR121","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12950-019-0218-y","volume":"16","author":"Q Que","year":"2019","unstructured":"Que Q, Guo X, Zhan L et al (2019) The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA\/CREB pathway in a rat model of knee osteoarthritis. J Inflamm (Lond) 16:13. https:\/\/doi.org\/10.1186\/s12950-019-0218-y","journal-title":"J Inflamm (Lond)"},{"key":"6090_CR122","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fimmu.2020.00111","volume":"11","author":"TL Fernandes","year":"2020","unstructured":"Fernandes TL, Gomoll AH, Lattermann C, Hernandez AJ, Bueno DF, Amano MT (2020) Macrophage: a potential target on cartilage regeneration. Front Immunol 11:111. https:\/\/doi.org\/10.3389\/fimmu.2020.00111","journal-title":"Front Immunol"},{"issue":"5","key":"6090_CR123","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41584-022-00749-9","volume":"18","author":"E Sanchez-Lopez","year":"2022","unstructured":"Sanchez-Lopez E, Coras R, Torres A, Lane NE, Guma M (2022) Synovial inflammation in osteoarthritis progression. Nat Rev Rheumatol 18(5):258\u2013275. https:\/\/doi.org\/10.1038\/s41584-022-00749-9","journal-title":"Nat Rev Rheumatol"},{"key":"6090_CR124","doi-asserted-by":"publisher","first-page":"997578","DOI":"10.3389\/fimmu.2022.997578","volume":"13","author":"J Chen","year":"2022","unstructured":"Chen J, Mei A, Wei Y et al (2022) GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol 13:997578. https:\/\/doi.org\/10.3389\/fimmu.2022.997578","journal-title":"Front Immunol"},{"issue":"5","key":"6090_CR125","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3892\/etm.2019.7347","volume":"17","author":"S Wan","year":"2019","unstructured":"Wan S, Sun H (2019) Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway. Exp Ther Med 17(5):3573\u20133579. https:\/\/doi.org\/10.3892\/etm.2019.7347","journal-title":"Exp Ther Med"},{"key":"6090_CR126","doi-asserted-by":"publisher","first-page":"602574","DOI":"10.3389\/fcell.2020.602574","volume":"8","author":"Y Fang","year":"2020","unstructured":"Fang Y, Ji L, Zhu C et al (2020) Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway. Front Cell Dev Biol 8:602574. https:\/\/doi.org\/10.3389\/fcell.2020.602574","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6090_CR127","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/cells9010070","volume":"9","author":"MY Wu","year":"2019","unstructured":"Wu MY, Lu JH (2019) Autophagy and macrophage functions: inflammatory response and phagocytosis. Cells 9(1):70. https:\/\/doi.org\/10.3390\/cells9010070","journal-title":"Cells"},{"issue":"1","key":"6090_CR128","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3892\/ijmm.2023.5326","volume":"53","author":"D Tan","year":"2024","unstructured":"Tan D, Huang Z, Zhao Z et al (2024) Single-cell sequencing, genetics, and epigenetics reveal mesenchymal stem cell senescence in osteoarthritis (Review). Int J Mol Med 53(1):2. https:\/\/doi.org\/10.3892\/ijmm.2023.5326","journal-title":"Int J Mol Med"},{"issue":"4","key":"6090_CR129","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/ijms22041742","volume":"22","author":"Q Hu","year":"2021","unstructured":"Hu Q, Ecker M (2021) Overview of MMP-13 as a promising target for the treatment of osteoarthritis. Int J Mol Sci 22(4):1742. https:\/\/doi.org\/10.3390\/ijms22041742","journal-title":"Int J Mol Sci"},{"key":"6090_CR130","doi-asserted-by":"publisher","first-page":"703110","DOI":"10.3389\/fmolb.2021.703110","volume":"8","author":"L Jiang","year":"2021","unstructured":"Jiang L, Lin J, Zhao S et al (2021) ADAMTS5 in osteoarthritis: biological functions, regulatory network, and potential targeting therapies. Front Mol Biosci 8:703110. https:\/\/doi.org\/10.3389\/fmolb.2021.703110","journal-title":"Front Mol Biosci"},{"issue":"1","key":"6090_CR131","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/med.21599","volume":"40","author":"MA Cinelli","year":"2020","unstructured":"Cinelli MA, Do HT, Miley GP, Silverman RB (2020) Inducible nitric oxide synthase: regulation, structure, and inhibition. Med Res Rev 40(1):158\u2013189. https:\/\/doi.org\/10.1002\/med.21599","journal-title":"Med Res Rev"},{"issue":"7","key":"6090_CR132","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2022.02.011","volume":"185","author":"SE Anton","year":"2022","unstructured":"Anton SE, Kayser C, Maiellaro I et al (2022) Receptor-associated independent cAMP nanodomains mediate spatiotemporal specificity of GPCR signaling. Cell 185(7):1130-1142.e11. https:\/\/doi.org\/10.1016\/j.cell.2022.02.011","journal-title":"Cell"},{"issue":"8","key":"6090_CR133","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, Liu Z, Ilyas I et al (2021) GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci 17(8):2050\u20132068. https:\/\/doi.org\/10.7150\/ijbs.59965","journal-title":"Int J Biol Sci"},{"key":"6090_CR134","doi-asserted-by":"publisher","first-page":"1355503","DOI":"10.3389\/fimmu.2024.1355503","volume":"15","author":"S Li","year":"2024","unstructured":"Li S, Du J, Huang Y et al (2024) From hyperglycemia to intervertebral disc damage: exploring diabetic-induced disc degeneration. Front Immunol 15:1355503. https:\/\/doi.org\/10.3389\/fimmu.2024.1355503","journal-title":"Front Immunol"},{"issue":"1","key":"6090_CR135","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","volume":"12","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L et al (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep 12(1):1567. https:\/\/doi.org\/10.1038\/s41598-022-05323-7","journal-title":"Sci Rep"},{"issue":"8","key":"6090_CR136","first-page":"4800","volume":"11","author":"J Mei","year":"2019","unstructured":"Mei J, Sun J, Wu J, Zheng X (2019) Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. Am J Transl Res 11(8):4800\u20134808","journal-title":"Am J Transl Res"},{"issue":"11","key":"6090_CR137","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00592-023-02135-7","volume":"60","author":"K Oezer","year":"2023","unstructured":"Oezer K, Kolibabka M, Gassenhuber J et al (2023) The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy. Acta Diabetol 60(11):1551\u20131565. https:\/\/doi.org\/10.1007\/s00592-023-02135-7","journal-title":"Acta Diabetol"},{"key":"6090_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","volume":"182","author":"G Bendotti","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res 182:106320. https:\/\/doi.org\/10.1016\/j.phrs.2022.106320","journal-title":"Pharmacol Res"},{"issue":"2","key":"6090_CR139","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032008","volume":"7","author":"Y Li","year":"2012","unstructured":"Li Y, Chigurupati S, Holloway HW et al (2012) Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE 7(2):e32008. https:\/\/doi.org\/10.1371\/journal.pone.0032008","journal-title":"PLoS ONE"},{"issue":"3","key":"6090_CR140","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10571-012-9900-9","volume":"33","author":"H Sun","year":"2013","unstructured":"Sun H, Knippenberg S, Thau N et al (2013) Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 33(3):347\u2013357. https:\/\/doi.org\/10.1007\/s10571-012-9900-9","journal-title":"Cell Mol Neurobiol"},{"issue":"7","key":"6090_CR141","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.13720","volume":"174","author":"M Xu","year":"2017","unstructured":"Xu M, Wu HY, Liu H, Gong N, Wang YR, Wang YX (2017) Morroniside, a secoiridoid glycoside from Cornus officinalis, attenuates neuropathic pain by activation of spinal glucagon-like peptide-1 receptors. Br J Pharmacol 174(7):580\u2013590. https:\/\/doi.org\/10.1111\/bph.13720","journal-title":"Br J Pharmacol"},{"issue":"15","key":"6090_CR142","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1523\/JNEUROSCI.4703-13.2014","volume":"34","author":"N Gong","year":"2014","unstructured":"Gong N, Xiao Q, Zhu B et al (2014) Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity. J Neurosci 34(15):5322\u20135334. https:\/\/doi.org\/10.1523\/JNEUROSCI.4703-13.2014","journal-title":"J Neurosci"},{"issue":"4","key":"6090_CR143","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","volume":"55","author":"CH Lee","year":"2018","unstructured":"Lee CH, Jeon SJ, Cho KS et al (2018) Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses. Mol Neurobiol 55(4):3007\u20133020. https:\/\/doi.org\/10.1007\/s12035-017-0550-2","journal-title":"Mol Neurobiol"},{"issue":"1","key":"6090_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-65442-1","volume":"14","author":"Y Ruska","year":"2024","unstructured":"Ruska Y, Csibi A, Dorogh\u00e1zi B et al (2024) Topography of the GLP-1\/GLP-1 receptor system in the spinal cord of male mice. Sci Rep 14(1):14403. https:\/\/doi.org\/10.1038\/s41598-024-65442-1","journal-title":"Sci Rep"},{"issue":"8","key":"6090_CR145","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jnr.22001","volume":"87","author":"BA Buhren","year":"2009","unstructured":"Buhren BA, Gasis M, Thorens B, M\u00fcller HW, Bosse F (2009) Glucose-dependent insulinotropic polypeptide (GIP) and its receptor (GIPR): cellular localization, lesion-affected expression, and impaired regenerative axonal growth. J Neurosci Res 87(8):1858\u20131870. https:\/\/doi.org\/10.1002\/jnr.22001","journal-title":"J Neurosci Res"},{"key":"6090_CR146","doi-asserted-by":"publisher","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA (2020) Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol 180:114187. https:\/\/doi.org\/10.1016\/j.bcp.2020.114187","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"6090_CR147","doi-asserted-by":"publisher","first-page":"2292461","DOI":"10.1080\/21688370.2023.2292461","volume":"12","author":"EM Rhea","year":"2024","unstructured":"Rhea EM, Babin A, Thomas P et al (2024) Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases. Tissue Barriers 12(4):2292461. https:\/\/doi.org\/10.1080\/21688370.2023.2292461","journal-title":"Tissue Barriers"},{"issue":"7","key":"6090_CR148","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s11095-022-03193-2","volume":"39","author":"KM Huttunen","year":"2022","unstructured":"Huttunen KM, Terasaki T, Urtti A, Montaser AB, Uchida Y (2022) Pharmacoproteomics of brain barrier transporters and substrate design for the brain targeted drug delivery. Pharm Res 39(7):1363\u20131392. https:\/\/doi.org\/10.1007\/s11095-022-03193-2","journal-title":"Pharm Res"},{"issue":"9","key":"6090_CR149","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1089\/neu.2020.7413","volume":"38","author":"LY Jin","year":"2021","unstructured":"Jin LY, Li J, Wang KF et al (2021) Blood-spinal cord barrier in spinal cord injury: a review. J Neurotrauma 38(9):1203\u20131224. https:\/\/doi.org\/10.1089\/neu.2020.7413","journal-title":"J Neurotrauma"},{"issue":"5","key":"6090_CR150","first-page":"4837","volume":"8","author":"H Li","year":"2015","unstructured":"Li H, Jia Z, Li G et al (2015) Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway. Int J Clin Exp Pathol 8(5):4837\u20134843","journal-title":"Int J Clin Exp Pathol"},{"key":"6090_CR151","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.jchemneu.2022.102079","volume":"121","author":"DA Mandour","year":"2022","unstructured":"Mandour DA, Shalaby SM, Bendary MA (2022) Spinal cord-wide structural disruption in type 2 diabetes rescued by exenatide \u201ca glucagon-like peptide-1 analogue\u201d via down-regulating inflammatory, oxidative stress and apoptotic signaling pathways. J Chem Neuroanat 121:102079. https:\/\/doi.org\/10.1016\/j.jchemneu.2022.102079","journal-title":"J Chem Neuroanat"},{"issue":"4","key":"6090_CR152","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.7150\/ijbs.68974","volume":"18","author":"Z Qian","year":"2022","unstructured":"Qian Z, Chen H, Xia M et al (2022) Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury. Int J Biol Sci 18(4):1328\u20131346. https:\/\/doi.org\/10.7150\/ijbs.68974","journal-title":"Int J Biol Sci"},{"issue":"7","key":"6090_CR153","doi-asserted-by":"publisher","first-page":"e14835","DOI":"10.1111\/cns.14835","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao X, Li QP, Hao JR et al (2024) Therapeutic effects of exendin-4 on spinal cord injury via restoring autophagy function and decreasing necroptosis in neuron. CNS Neurosci Ther 30(7):e14835. https:\/\/doi.org\/10.1111\/cns.14835","journal-title":"CNS Neurosci Ther"},{"key":"6090_CR154","doi-asserted-by":"publisher","first-page":"134747","DOI":"10.1016\/j.neulet.2020.134747","volume":"720","author":"D Zhang","year":"2020","unstructured":"Zhang D, Yu D, Mei X, Lv G (2020) Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model. Neurosci Lett 720:134747. https:\/\/doi.org\/10.1016\/j.neulet.2020.134747","journal-title":"Neurosci Lett"},{"issue":"6","key":"6090_CR155","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.3390\/ijms22062971","volume":"22","author":"S Takaku","year":"2021","unstructured":"Takaku S, Tsukamoto M, Niimi N, Yako H, Sango K (2021) Exendin-4 promotes Schwann cell survival\/migration and myelination in vitro. Int J Mol Sci 22(6):2971. https:\/\/doi.org\/10.3390\/ijms22062971","journal-title":"Int J Mol Sci"},{"key":"6090_CR156","doi-asserted-by":"publisher","first-page":"103857","DOI":"10.1016\/j.redox.2025.103857","volume":"86","author":"M Xia","year":"2025","unstructured":"Xia M, Li C, Zhang Y et al (2025) GLP-1R activation restores Gas6-driven efferocytosis in senescent foamy macrophages to promote neural repair. Redox Biol 86:103857. https:\/\/doi.org\/10.1016\/j.redox.2025.103857","journal-title":"Redox Biol"},{"key":"6090_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2025.09.001","author":"T Qin","year":"2025","unstructured":"Qin T, Jiang T, Zhou Z et al (2025) Treg-microglia partnership in the injured spinal cord preserves Treg cell function and regulates microglial cholesterol metabolism. Neuron. https:\/\/doi.org\/10.1016\/j.neuron.2025.09.001","journal-title":"Neuron"},{"issue":"8","key":"6090_CR158","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jnr.23993","volume":"95","author":"Y Wu","year":"2017","unstructured":"Wu Y, Lin YH, Shi LL et al (2017) Temporal kinetics of CD8+ CD28+ and CD8+ CD28- T lymphocytes in the injured rat spinal cord. J Neurosci Res 95(8):1666\u20131676. https:\/\/doi.org\/10.1002\/jnr.23993","journal-title":"J Neurosci Res"},{"issue":"2","key":"6090_CR159","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbrc.2019.03.002","volume":"512","author":"Z Liu","year":"2019","unstructured":"Liu Z, Zhang H, Xia H et al (2019) CD8 T cell-derived perforin aggravates secondary spinal cord injury through destroying the blood-spinal cord barrier. Biochem Biophys Res Commun 512(2):367\u2013372. https:\/\/doi.org\/10.1016\/j.bbrc.2019.03.002","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"6090_CR160","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01724-y","volume":"20","author":"W Xiong","year":"2022","unstructured":"Xiong W, Li C, Kong G et al (2022) Treg cell-derived exosomes miR-709 attenuates microglia pyroptosis and promotes motor function recovery after spinal cord injury. J Nanobiotechnol 20(1):529. https:\/\/doi.org\/10.1186\/s12951-022-01724-y","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"6090_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02089-6","volume":"21","author":"G Kong","year":"2023","unstructured":"Kong G, Xiong W, Li C et al (2023) Treg cells-derived exosomes promote blood-spinal cord barrier repair and motor function recovery after spinal cord injury by delivering miR-2861. J Nanobiotechnol 21(1):364. https:\/\/doi.org\/10.1186\/s12951-023-02089-6","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"6090_CR162","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s40001-023-01122-6","volume":"28","author":"H Chen","year":"2023","unstructured":"Chen H, Peng H, Wang PC, Zou T, Feng XM, Wan BW (2023) Role of regulatory T cells in spinal cord injury. Eur J Med Res 28(1):163. https:\/\/doi.org\/10.1186\/s40001-023-01122-6","journal-title":"Eur J Med Res"},{"issue":"1","key":"6090_CR163","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12974-022-02627-3","volume":"19","author":"ES Fisher","year":"2022","unstructured":"Fisher ES, Amarante MA, Lowry N et al (2022) Single cell profiling of CD45+ spinal cord cells reveals microglial and B cell heterogeneity and crosstalk following spinal cord injury. J Neuroinflammation 19(1):266. https:\/\/doi.org\/10.1186\/s12974-022-02627-3","journal-title":"J Neuroinflammation"},{"issue":"1","key":"6090_CR164","doi-asserted-by":"publisher","first-page":"e202000907","DOI":"10.26508\/lsa.202000907","volume":"4","author":"M Cohen","year":"2021","unstructured":"Cohen M, Giladi A, Raposo C et al (2021) Meningeal lymphoid structures are activated under acute and chronic spinal cord pathologies. Life Sci Alliance 4(1):e202000907. https:\/\/doi.org\/10.26508\/lsa.202000907","journal-title":"Life Sci Alliance"},{"issue":"8","key":"6090_CR165","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","volume":"19","author":"Y Sato","year":"2023","unstructured":"Sato Y, Silina K, van den Broek M, Hirahara K, Yanagita M (2023) The roles of tertiary lymphoid structures in chronic diseases. Nat Rev Nephrol 19(8):525\u2013537. https:\/\/doi.org\/10.1038\/s41581-023-00706-z","journal-title":"Nat Rev Nephrol"},{"issue":"6576","key":"6090_CR166","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS (2022) Tertiary lymphoid structures in cancer. Science 375(6576):eabf9419. https:\/\/doi.org\/10.1126\/science.abf9419","journal-title":"Science"},{"issue":"6","key":"6090_CR167","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M, Usuelli V, Dellepiane S et al (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab 36(6):1302-1319.e12. https:\/\/doi.org\/10.1016\/j.cmet.2024.05.001","journal-title":"Cell Metab"},{"issue":"1","key":"6090_CR168","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10020-022-00574-6","volume":"28","author":"Q Xu","year":"2022","unstructured":"Xu Q, Zhang X, Li T, Shao S (2022) Exenatide regulates Th17\/Treg balance via PI3K\/Akt\/FoxO1 pathway in db\/db mice. Mol Med 28(1):144. https:\/\/doi.org\/10.1186\/s10020-022-00574-6","journal-title":"Mol Med"},{"issue":"4","key":"6090_CR169","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","volume":"53","author":"I Hadjiyanni","year":"2010","unstructured":"Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ (2010) Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53(4):730\u2013740. https:\/\/doi.org\/10.1007\/s00125-009-1643-x","journal-title":"Diabetologia"},{"issue":"1","key":"6090_CR170","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1038\/s41598-017-03792-9","volume":"7","author":"L Rachmany","year":"2017","unstructured":"Rachmany L, Tweedie D, Rubovitch V et al (2017) Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degeneration. Sci Rep 7(1):3735. https:\/\/doi.org\/10.1038\/s41598-017-03792-9","journal-title":"Sci Rep"},{"issue":"9","key":"6090_CR171","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/acn3.99","volume":"1","author":"B DellaValle","year":"2014","unstructured":"DellaValle B, Hempel C, Johansen FF, Kurtzhals JAL (2014) GLP-1 improves neuropathology after murine cold lesion brain trauma. Ann Clin Transl Neurol 1(9):721\u2013732. https:\/\/doi.org\/10.1002\/acn3.99","journal-title":"Ann Clin Transl Neurol"},{"key":"6090_CR172","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.nbd.2018.11.023","volume":"124","author":"M Bader","year":"2019","unstructured":"Bader M, Li Y, Lecca D et al (2019) Pharmacokinetics and efficacy of PT302, a sustained-release exenatide formulation, in a murine model of mild traumatic brain injury. Neurobiol Dis 124:439\u2013453. https:\/\/doi.org\/10.1016\/j.nbd.2018.11.023","journal-title":"Neurobiol Dis"},{"key":"6090_CR173","doi-asserted-by":"publisher","first-page":"113113","DOI":"10.1016\/j.expneurol.2019.113113","volume":"324","author":"Y Li","year":"2020","unstructured":"Li Y, Glotfelty EJ, Namdar I et al (2020) Neurotrophic and neuroprotective effects of a monomeric GLP-1\/GIP\/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury. Exp Neurol 324:113113. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113113","journal-title":"Exp Neurol"},{"issue":"6","key":"6090_CR174","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/jnc.13169","volume":"135","author":"Y Li","year":"2015","unstructured":"Li Y, Bader M, Tamargo I et al (2015) Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J Neurochem 135(6):1203\u20131217. https:\/\/doi.org\/10.1111\/jnc.13169","journal-title":"J Neurochem"},{"key":"6090_CR175","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.expneurol.2016.11.005","volume":"288","author":"IA Tamargo","year":"2017","unstructured":"Tamargo IA, Bader M, Li Y et al (2017) Novel GLP-1R\/GIPR co-agonist \u201ctwincretin\u201d is neuroprotective in cell and rodent models of mild traumatic brain injury. Exp Neurol 288:176\u2013186. https:\/\/doi.org\/10.1016\/j.expneurol.2016.11.005","journal-title":"Exp Neurol"},{"issue":"4","key":"6090_CR176","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5607\/en.2017.26.4.227","volume":"26","author":"S Kim","year":"2017","unstructured":"Kim S, Jeong J, Jung HS et al (2017) Anti-inflammatory effect of glucagon like peptide-1 receptor agonist, exendin-4, through modulation of IB1\/JIP1 expression and JNK signaling in stroke. Exp Neurobiol 26(4):227\u2013239. https:\/\/doi.org\/10.5607\/en.2017.26.4.227","journal-title":"Exp Neurobiol"},{"issue":"12","key":"6090_CR177","doi-asserted-by":"publisher","first-page":"e82016","DOI":"10.1371\/journal.pone.0082016","volume":"8","author":"K Eakin","year":"2013","unstructured":"Eakin K, Li Y, Chiang YH et al (2013) Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS ONE 8(12):e82016. https:\/\/doi.org\/10.1371\/journal.pone.0082016","journal-title":"PLoS ONE"},{"issue":"1","key":"6090_CR178","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.numecd.2020.09.002","volume":"31","author":"B Bai","year":"2021","unstructured":"Bai B, Li D, Xue G et al (2021) The novel GLP-1\/GIP dual agonist DA3-CH is more effective than liraglutide in reducing endoplasmic reticulum stress in diabetic rats with cerebral ischemia-reperfusion injury. Nutr Metab Cardiovasc Dis 31(1):333\u2013343. https:\/\/doi.org\/10.1016\/j.numecd.2020.09.002","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"6090_CR179","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.expneurol.2012.10.001","volume":"239","author":"D Tweedie","year":"2013","unstructured":"Tweedie D, Rachmany L, Rubovitch V et al (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol 239:170\u2013182. https:\/\/doi.org\/10.1016\/j.expneurol.2012.10.001","journal-title":"Exp Neurol"},{"key":"6090_CR180","doi-asserted-by":"publisher","first-page":"106715","DOI":"10.1016\/j.intimp.2020.106715","volume":"86","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yi T, Cheng S, Zhang S (2020) Glucagon-like peptide-1 receptor agonist exendin-4 improves neurological outcomes by attenuating TBI- induced inflammatory responses and MAPK activation in rats. Int Immunopharmacol 86:106715. https:\/\/doi.org\/10.1016\/j.intimp.2020.106715","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"6090_CR181","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/jcbfm.2015.126","volume":"35","author":"CT Chien","year":"2015","unstructured":"Chien CT, Jou MJ, Cheng TY, Yang CH, Yu TY, Li PC (2015) Exendin-4-loaded PLGA microspheres relieve cerebral ischemia\/reperfusion injury and neurologic deficits through long-lasting bioactivity-mediated phosphorylated Akt\/eNOS signaling in rats. J Cereb Blood Flow Metab 35(11):1790\u20131803. https:\/\/doi.org\/10.1038\/jcbfm.2015.126","journal-title":"J Cereb Blood Flow Metab"},{"issue":"48","key":"6090_CR182","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1523\/JNEUROSCI.1799-17.2017","volume":"37","author":"HY Wu","year":"2017","unstructured":"Wu HY, Tang XQ, Mao XF, Wang YX (2017) Autocrine interleukin-10 mediates glucagon-like peptide-1 receptor-induced spinal microglial \u03b2-endorphin expression. J Neurosci 37(48):11701\u201311714. https:\/\/doi.org\/10.1523\/JNEUROSCI.1799-17.2017","journal-title":"J Neurosci"},{"issue":"1","key":"6090_CR183","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12974-020-01973-4","volume":"17","author":"H Fan","year":"2020","unstructured":"Fan H, Tang HB, Chen Z et al (2020) Inhibiting HMGB1-RAGE axis prevents pro-inflammatory macrophages\/microglia polarization and affords neuroprotection after spinal cord injury. J Neuroinflammation 17(1):295. https:\/\/doi.org\/10.1186\/s12974-020-01973-4","journal-title":"J Neuroinflammation"},{"issue":"2","key":"6090_CR184","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1007\/s12035-024-04394-z","volume":"62","author":"CL Xiao","year":"2025","unstructured":"Xiao CL, Lai HT, Zhou JJ, Liu WY, Zhao M, Zhao K (2025) Nrf2 signaling pathway: focus on oxidative stress in spinal cord injury. Mol Neurobiol 62(2):2230\u20132249. https:\/\/doi.org\/10.1007\/s12035-024-04394-z","journal-title":"Mol Neurobiol"},{"issue":"10","key":"6090_CR185","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/jnr.25221","volume":"101","author":"M Yu","year":"2023","unstructured":"Yu M, Wang Z, Wang D, Aierxi M, Ma Z, Wang Y (2023) Oxidative stress following spinal cord injury: from molecular mechanisms to therapeutic targets. J Neurosci Res 101(10):1538\u20131554. https:\/\/doi.org\/10.1002\/jnr.25221","journal-title":"J Neurosci Res"},{"issue":"6","key":"6090_CR186","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00204-023-03476-6","volume":"97","author":"B Wang","year":"2023","unstructured":"Wang B, Wang Y, Zhang J et al (2023) ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. Arch Toxicol 97(6):1439\u20131451. https:\/\/doi.org\/10.1007\/s00204-023-03476-6","journal-title":"Arch Toxicol"},{"key":"6090_CR187","doi-asserted-by":"publisher","first-page":"tkac054","DOI":"10.1093\/burnst\/tkac054","volume":"11","author":"Y Jin","year":"2023","unstructured":"Jin Y, Song Y, Lin J et al (2023) Role of inflammation in neurological damage and regeneration following spinal cord injury and its therapeutic implications. Burns Trauma 11:tkac054. https:\/\/doi.org\/10.1093\/burnst\/tkac054","journal-title":"Burns Trauma"},{"issue":"9","key":"6090_CR188","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5483\/BMBRep.2024-0067","volume":"57","author":"J Ko","year":"2024","unstructured":"Ko J, Jang S, Jang S et al (2024) Glucose-dependent insulinotropic polypeptide (GIP) alleviates ferroptosis in aging-induced brain damage through the Epac\/Rap1 signaling pathway. BMB Rep 57(9):417\u2013423. https:\/\/doi.org\/10.5483\/BMBRep.2024-0067","journal-title":"BMB Rep"},{"key":"6090_CR189","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuropharm.2017.09.040","volume":"128","author":"Z Xie","year":"2018","unstructured":"Xie Z, Enkhjargal B, Wu L et al (2018) Exendin-4 attenuates neuronal death via GLP-1R\/PI3K\/Akt pathway in early brain injury after subarachnoid hemorrhage in rats. Neuropharmacology 128:142\u2013151. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.09.040","journal-title":"Neuropharmacology"},{"key":"6090_CR190","doi-asserted-by":"publisher","first-page":"116566","DOI":"10.1016\/j.lfs.2019.116566","volume":"231","author":"W Yan","year":"2019","unstructured":"Yan W, Pang M, Yu Y et al (2019) The neuroprotection of liraglutide on diabetic cognitive deficits is associated with improved hippocampal synapses and inhibited neuronal apoptosis. Life Sci 231:116566. https:\/\/doi.org\/10.1016\/j.lfs.2019.116566","journal-title":"Life Sci"},{"key":"6090_CR191","doi-asserted-by":"publisher","first-page":"109647","DOI":"10.1016\/j.intimp.2022.109647","volume":"115","author":"MA Sadek","year":"2023","unstructured":"Sadek MA, Kandil EA, El Sayed NS, Sayed HM, Rabie MA (2023) Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: Involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway. Int Immunopharmacol 115:109647. https:\/\/doi.org\/10.1016\/j.intimp.2022.109647","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"6090_CR192","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.4103\/1673-5374.373674","volume":"18","author":"SS Chambel","year":"2023","unstructured":"Chambel SS, Cruz CD (2023) Axonal growth inhibitors and their receptors in spinal cord injury: from biology to clinical translation. Neural Regen Res 18(12):2573\u20132581. https:\/\/doi.org\/10.4103\/1673-5374.373674","journal-title":"Neural Regen Res"},{"issue":"1","key":"6090_CR193","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.expneurol.2011.05.001","volume":"235","author":"JK Lee","year":"2012","unstructured":"Lee JK, Zheng B (2012) Role of myelin-associated inhibitors in axonal repair after spinal cord injury. Exp Neurol 235(1):33\u201342. https:\/\/doi.org\/10.1016\/j.expneurol.2011.05.001","journal-title":"Exp Neurol"},{"issue":"9","key":"6090_CR194","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/1873-3468.13740","volume":"594","author":"E Nikulina","year":"2020","unstructured":"Nikulina E, Gkioka V, Siddiq MM et al (2020) Myelin-associated glycoprotein inhibits neurite outgrowth through inactivation of the small GTPase Rap1. FEBS Lett 594(9):1389\u20131402. https:\/\/doi.org\/10.1002\/1873-3468.13740","journal-title":"FEBS Lett"},{"issue":"1","key":"6090_CR195","doi-asserted-by":"publisher","first-page":"e13098","DOI":"10.1111\/bpa.13098","volume":"33","author":"C Schwaiger","year":"2023","unstructured":"Schwaiger C, Haider T, Endmayr V et al (2023) Dynamic induction of the myelin-associated growth inhibitor Nogo-A in perilesional plasticity regions after human spinal cord injury. Brain Pathol 33(1):e13098. https:\/\/doi.org\/10.1111\/bpa.13098","journal-title":"Brain Pathol"},{"key":"6090_CR196","doi-asserted-by":"publisher","first-page":"107748","DOI":"10.1016\/j.neuropharm.2019.107748","volume":"158","author":"X Yang","year":"2019","unstructured":"Yang X, Feng P, Zhang X et al (2019) The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology 158:107748. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107748","journal-title":"Neuropharmacology"},{"issue":"3","key":"6090_CR197","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jcp.29204","volume":"235","author":"W He","year":"2020","unstructured":"He W, Wang H, Zhao C, Tian X, Li L, Wang H (2020) Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke. J Cell Physiol 235(3):2986\u20133001. https:\/\/doi.org\/10.1002\/jcp.29204","journal-title":"J Cell Physiol"},{"key":"6090_CR198","doi-asserted-by":"publisher","first-page":"750726","DOI":"10.3389\/fnmol.2021.750726","volume":"14","author":"Z Xie","year":"2021","unstructured":"Xie Z, Enkhjargal B, Nathanael M et al (2021) Exendin-4 preserves blood-brain barrier integrity via glucagon-like peptide 1 receptor\/activated protein kinase-dependent nuclear factor-kappa B\/matrix metalloproteinase-9 inhibition after subarachnoid hemorrhage in rat. Front Mol Neurosci 14:750726. https:\/\/doi.org\/10.3389\/fnmol.2021.750726","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"6090_CR199","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s43587-025-00869-3","volume":"5","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen H, Feng Y et al (2025) Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice. Nat Aging 5(6):1097\u20131113. https:\/\/doi.org\/10.1038\/s43587-025-00869-3","journal-title":"Nat Aging"},{"issue":"3","key":"6090_CR200","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cns.13791","volume":"28","author":"S Song","year":"2022","unstructured":"Song S, Guo R, Mehmood A et al (2022) Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway. CNS Neurosci Ther 28(3):422\u2013434. https:\/\/doi.org\/10.1111\/cns.13791","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"6090_CR201","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11011-021-00879-1","volume":"37","author":"B Cao","year":"2022","unstructured":"Cao B, Zhang Y, Chen J, Wu P, Dong Y, Wang Y (2022) Neuroprotective effects of liraglutide against inflammation through the AMPK\/NF-\u03baB pathway in a mouse model of Parkinson\u2019s disease. Metab Brain Dis 37(2):451\u2013462. https:\/\/doi.org\/10.1007\/s11011-021-00879-1","journal-title":"Metab Brain Dis"},{"issue":"2","key":"6090_CR202","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1152\/physrev.00017.2017","volume":"98","author":"AP Tran","year":"2018","unstructured":"Tran AP, Warren PM, Silver J (2018) The biology of regeneration failure and success after spinal cord injury. Physiol Rev 98(2):881\u2013917. https:\/\/doi.org\/10.1152\/physrev.00017.2017","journal-title":"Physiol Rev"},{"issue":"1","key":"6090_CR203","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12264-024-01258-3","volume":"41","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Liu H, Dai Z, He C, Qin S, Su Z (2025) From physiology to pathology of astrocytes: highlighting their potential as therapeutic targets for CNS injury. Neurosci Bull 41(1):131\u2013154. https:\/\/doi.org\/10.1007\/s12264-024-01258-3","journal-title":"Neurosci Bull"},{"issue":"7","key":"6090_CR204","doi-asserted-by":"publisher","first-page":"a041356","DOI":"10.1101\/cshperspect.a041356","volume":"16","author":"SA Liddelow","year":"2024","unstructured":"Liddelow SA, Olsen ML, Sofroniew MV (2024) Reactive astrocytes and emerging roles in central nervous system (CNS) disorders. Cold Spring Harb Perspect Biol 16(7):a041356. https:\/\/doi.org\/10.1101\/cshperspect.a041356","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"6090_CR205","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/ddr.21439","volume":"79","author":"Y Fang","year":"2018","unstructured":"Fang Y, Jiang D, Wang Y et al (2018) Neuroprotection of rhGLP-1 in diabetic rats with cerebral ischemia\/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis. Drug Dev Res 79(6):249\u2013259. https:\/\/doi.org\/10.1002\/ddr.21439","journal-title":"Drug Dev Res"},{"issue":"12","key":"6090_CR206","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1111\/cns.14308","volume":"29","author":"C Lv","year":"2023","unstructured":"Lv C, Han S, Sha Z et al (2023) Cerebral glucagon-like peptide-1 receptor activation alleviates traumatic brain injury by glymphatic system regulation in mice. CNS Neurosci Ther 29(12):3876\u20133888. https:\/\/doi.org\/10.1111\/cns.14308","journal-title":"CNS Neurosci Ther"},{"issue":"22","key":"6090_CR207","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1089\/neu.2015.4229","volume":"33","author":"YW Yu","year":"2016","unstructured":"Yu YW, Hsieh TH, Chen KY et al (2016) Glucose-dependent insulinotropic polypeptide ameliorates mild traumatic brain injury-induced cognitive and sensorimotor deficits and neuroinflammation in rats. J Neurotrauma 33(22):2044\u20132054. https:\/\/doi.org\/10.1089\/neu.2015.4229","journal-title":"J Neurotrauma"},{"issue":"1","key":"6090_CR208","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","volume":"16","author":"Y Shan","year":"2019","unstructured":"Shan Y, Tan S, Lin Y et al (2019) The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. J Neuroinflammation 16(1):242. https:\/\/doi.org\/10.1186\/s12974-019-1638-6","journal-title":"J Neuroinflammation"},{"issue":"3","key":"6090_CR209","doi-asserted-by":"publisher","first-page":"943","DOI":"10.14336\/AD.2021.1029","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Liu C, Shi R et al (2022) Blocking C3d+\/GFAP+ A1 astrocyte conversion with semaglutide attenuates blood-brain barrier disruption in mice after ischemic stroke. Aging Dis 13(3):943\u2013959. https:\/\/doi.org\/10.14336\/AD.2021.1029","journal-title":"Aging Dis"},{"key":"6090_CR210","doi-asserted-by":"publisher","first-page":"173581","DOI":"10.1016\/j.ejphar.2020.173581","volume":"887","author":"J Huang","year":"2020","unstructured":"Huang J, Liu Y, Cheng L et al (2020) Glucagon-like peptide-1 cleavage product GLP-1(9\u201336) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes. Eur J Pharmacol 887:173581. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173581","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"6090_CR211","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/bc.bc_38_24","volume":"10","author":"R Mi","year":"2024","unstructured":"Mi R, Cheng H, Chen R et al (2024) Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia\/reperfusion in rats. Brain Circ 10(4):354\u2013365. https:\/\/doi.org\/10.4103\/bc.bc_38_24","journal-title":"Brain Circ"},{"issue":"5","key":"6090_CR212","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaneurol.2025.0353","volume":"82","author":"H Tang","year":"2025","unstructured":"Tang H, Donahoo WT, DeKosky ST et al (2025) GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias. JAMA Neurol 82(5):439\u2013449. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0353","journal-title":"JAMA Neurol"},{"key":"6090_CR213","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202514854","author":"H Wang","year":"2026","unstructured":"Wang H, Sun Y, Wang S et al (2026) Spatiotemporal co-delivery of hydrogen and magnesium via microneedle patches for neuroinflammation modulation after spinal cord injury: a multi-modal in vivo study. Small. https:\/\/doi.org\/10.1002\/smll.202514854","journal-title":"Small"},{"issue":"15","key":"6090_CR214","doi-asserted-by":"publisher","first-page":"6391","DOI":"10.1021\/acs.nanolett.2c02259","volume":"22","author":"M Han","year":"2022","unstructured":"Han M, Yang H, Lu X et al (2022) Three-dimensional-cultured MSC-derived exosome-hydrogel hybrid microneedle array patch for spinal cord repair. Nano Lett 22(15):6391\u20136401. https:\/\/doi.org\/10.1021\/acs.nanolett.2c02259","journal-title":"Nano Lett"},{"issue":"13","key":"6090_CR215","doi-asserted-by":"publisher","first-page":"e2105586","DOI":"10.1002\/advs.202105586","volume":"9","author":"L Fan","year":"2022","unstructured":"Fan L, Liu C, Chen X et al (2022) Exosomes-loaded electroconductive hydrogel synergistically promotes tissue repair after spinal cord injury via immunoregulation and enhancement of myelinated axon growth. Adv Sci (Weinh) 9(13):e2105586. https:\/\/doi.org\/10.1002\/advs.202105586","journal-title":"Adv Sci (Weinh)"},{"issue":"22","key":"6090_CR216","doi-asserted-by":"publisher","first-page":"22928","DOI":"10.1021\/acsnano.3c08046","volume":"17","author":"B Zhu","year":"2023","unstructured":"Zhu B, Gu G, Ren J et al (2023) Schwann cell-derived exosomes and methylprednisolone composite patch for spinal cord injury repair. ACS Nano 17(22):22928\u201322943. https:\/\/doi.org\/10.1021\/acsnano.3c08046","journal-title":"ACS Nano"},{"issue":"41","key":"6090_CR217","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202304896","volume":"35","author":"L Xiao","year":"2023","unstructured":"Xiao L, Xie P, Ma J et al (2023) A bioinspired injectable, adhesive, and self-healing hydrogel with dual hybrid network for neural regeneration after spinal cord injury. Adv Mater 35(41):e2304896. https:\/\/doi.org\/10.1002\/adma.202304896","journal-title":"Adv Mater"},{"issue":"11","key":"6090_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101292","volume":"4","author":"AI d\u2019Aquino","year":"2023","unstructured":"d\u2019Aquino AI, Maikawa CL, Nguyen LT et al (2023) Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management. Cell Rep Med 4(11):101292. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101292","journal-title":"Cell Rep Med"},{"issue":"1","key":"6090_CR219","doi-asserted-by":"publisher","first-page":"2557938","DOI":"10.1080\/10717544.2025.2557938","volume":"32","author":"C Zhang","year":"2025","unstructured":"Zhang C, Long L, Hu H et al (2025) Integrating micro-needle jet injection and sustained GLP-1 therapy with structured feeding: a comprehensive strategy for obesity management. Drug Deliv 32(1):2557938. https:\/\/doi.org\/10.1080\/10717544.2025.2557938","journal-title":"Drug Deliv"},{"key":"6090_CR220","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04261-0","author":"H Zhang","year":"2026","unstructured":"Zhang H, Liu Y, Zhang S et al (2026) Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis. J Nanobiotechnol. https:\/\/doi.org\/10.1186\/s12951-026-04261-0","journal-title":"J Nanobiotechnol"},{"issue":"17","key":"6090_CR221","doi-asserted-by":"publisher","first-page":"7758","DOI":"10.7150\/thno.46821","volume":"10","author":"SMP Fletcher","year":"2020","unstructured":"Fletcher SMP, Choi M, Ogrodnik N, O\u2019Reilly MA (2020) A porcine model of transvertebral ultrasound and microbubble-mediated blood-spinal cord barrier opening. Theranostics 10(17):7758\u20137774. https:\/\/doi.org\/10.7150\/thno.46821","journal-title":"Theranostics"},{"issue":"4","key":"6090_CR222","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740\u2013756. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"issue":"3 Suppl","key":"6090_CR223","doi-asserted-by":"publisher","first-page":"84S","DOI":"10.1177\/2192568217703387","volume":"7","author":"MG Fehlings","year":"2017","unstructured":"Fehlings MG, Tetreault LA, Wilson JR et al (2017) A clinical practice guideline for the management of acute spinal cord injury: introduction, rationale, and scope. Global Spine J 7(3 Suppl):84S-94S. https:\/\/doi.org\/10.1177\/2192568217703387","journal-title":"Global Spine J"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06090-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06090-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06090-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:24:47Z","timestamp":1785515087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06090-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":223,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6090"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06090-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the author used ChatGPT and Gemini in order to improve language. After using this tool, the author reviewed and edited the content as needed and takes full responsibility for the content of the publication.","order":4,"name":"Ethics","label":"Declaration of Generative AI and AI-Assisted Technologies in the Manuscript Preparation Process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"798"}}